A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Experimental Therapeutics Bookmark and Share

Department of Experimental Therapeutics

The Laboratory of Vaccine Research (LVR) was originally formed by  Don J. Diamond, Ph.D. in 2000 to address priorities in vaccine research that would potentially impact patient outcomes at the City of Hope (COH) and other cancer centers worldwide.  The LVR later evolved into the Division of Translational Vaccine Research (TVR) in 2008, which has, since then, focused on the clinical translation of vaccine and therapeutic strategies to combat herpes viral infections, hematologic malignancies, and solid tumors. Our comprehensive program has now developed molecular vaccines and therapies that incorporate various technologies such as peptides and viral or bacterial vectors to directly elicit, or encode antigens that elicit, viral- or cancer-specific immune responses. Currently, the TVR has produced several agents that have advanced beyond pre-clinical testing into Phase I and II trials. The mission of the TVR is to continue progress in the development and testing of treatments with clinical benefit for cancer patients.  In 2014, the TVR was transformed into the Department of Experimental Therapeutics (ET).  The mission of the ET department will encompass the work of the TVR and broaden its scope to include more basic studies in basic and tumor immunology.

Human Cytomegalovirus
 
Allogeneic hematopoietic cell transplantation (HCT) is a therapy for which COH is a world leader and is effective for a range of life-threatening hematologic malignancies. However, one of the most difficult-to-treat complications can occur during the first 100 days post-HCT, which is infection with the highly prevalent beta-herpes virus known as human cytomegalovirus (HCMV).  HCMV rarely causes disease in healthy individuals, but can be life-threatening in HCT patients as a result of immunosuppression associated with treatment strategies aimed at preventing rejection or graft-versus-host disease (GVHD).  To improve outcomes for HCT recipients, the ET aims to substitute toxic antivirals with a vaccine that induces long-lasting, memory immune responses to HCMV, since antivirals are unable to generate adaptive immunity capable of preventing HCMV infection and disease.  Learn more.
 

Oncotherapeutics
 
Advanced pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and can be attributed to deficiencies in early detection methods and effective therapies. Overexpression of indoleamine 2,3-dioxygenase (IDO) in PDAC plays a major role in accelerating disease progression by suppressing antitumor immunity. shIDO-ST is a novel Salmonella typhimirium (ST)-based therapy that expresses a small hairpin (sh) RNA to specifically silence tumor-derived IDO with decreased toxicity. ST as an shRNA delivery vehicle offers superior penetration against desmoplastic PDAC tissue and anti-metastatic function due to its motility and affinity for poorly vascularized, hypoxic tissue.  Using bioluminescent forms of cell lines derived from pancreatic tumors, the TVR is able to employ advanced imaging techniques to follow therapeutic strategies in which Salmonella therapy is combined with proprietary adjuvant causing remarkable complete rejection of transplantable tumors.  Learn more.
 

Human Cytomegalovirus

Allogeneic hematopoietic cell transplantation (HCT) is a therapy for which City of Hope is a world leader and is effective for a range of life-threatening hematologic malignancies. However, one of the most difficult-to-treat complications can occur during the first 100 days post-HCT, which is infection with the highly prevalent beta-herpes virus known as human cytomegalovirus (HCMV).  HCMV rarely causes disease in healthy individuals, but can be life-threatening in HCT patients as a result of immunosuppression associated with treatment strategies aimed at preventing rejection or graft-versus-host disease (GVHD).  To improve outcomes for HCT recipients, the TVR aims to substitute toxic antivirals with a vaccine that induces long-lasting, memory immune responses to HCMV, since antivirals are unable to generate adaptive immunity capable of preventing HCMV infection and disease.
 
In allogeneic HCT, hematopoietic cells are obtained from suitable HLA matched related or unrelated volunteer donors (URD).  Pretransplant patients are treated with chemotherapy, with or without radiation therapy, to eradicate cancerous cells, and for suppressing the patient’s immune system to prevent it from attacking donor hematopoietic cells.  As a result, patients are vulnerable to pathogens and herpes virus infections, including CMV, as a result of immunosuppression associated with treatment strategies aimed at preventing rejection or graft-versus-host disease (GVHD).  Despite advances in development of antiviral therapy, the use of antivirals does not address the major risks of late-onset CMV disease, including reactivation and failure to reconstitute CMV-specific immunity.  Substituting toxic antivirals with a vaccine that harnesses the abundant native immune response to CMV may improve outcomes for HCT recipients.
 
Our first generation vaccine approach relied on a non-living synthetic portion of the virus called a peptide that has cleared its safety hurdle after a successful clinical trial in healthy volunteers. The vaccine peptides were named PADRE-CMV and Tet-CMV, respectively, and were developed with support of the National Cancer Institute sponsored Rapid Access to Interventional Development (NCI-RAID, currently called NCI-NExT) program.  After obtaining approval from the FDA, PADRE-CMV and Tet-CMV, with or without PF-03512676 adjuvant (a synthetic single stranded DNA containing bacterial CpG DNA motifs with immunostimulatory activity, produced by Pfizer, Inc.), were clinically evaluated for safety and immunogenicity in a Phase Ib dose-escalation clinical trial.  The achievement of the central goal of our phase Ib study in healthy adults supports further evaluation of Tet-CMV combined with PF-03512676 (renamed CMVPepVax)  in the HCT setting. A summary of the results of the trial was published in 2012. These promising results are the basis for CMVPepVax as a therapeutic vaccine, to improve outcomes of HCT recipients with uncontrolled CMV viremia. The phase Ib pilot trial was powered to evaluate safety of administering CMVPepVax to HLA matched allogeneic (MRD or URD) patients at risk for CMV complications ( Project 1 ).  To capitalize on the success of the pilot Phase Ib trial, NCI approved a fresh lot of vaccine to support a large multi-center Phase II study jointly with the University of Minnesota Comprehensive Cancer Center.  The goal of this Phase II clinical trial is to assess efficacy of CMVPepVax, in protecting against CMV reactivation and disease ( Project 2 ).
 
As a viral vector that can incorporate foreign antigens and protect against a challenge pathogen, modified vaccinia Ankara (MVA) virus is hypothesized to act as a powerful immunotherapeutic tool against multiple strains of CMV regardless of an individual’s HLA type (Projects 3-6). The potential value of MVA for the clinic stems from its ability to elicit strong humoral and T cell responses against diverse antigens. Studies in rodents and macaques affirm the safety of MVA, including protection against more virulent forms of poxviruses.  There are over 150 active clinical studies using MVA that are documented on the USPHS website.  Recent trials have shown MVA is well tolerated and immunogenic when administered to HCT recipients, indicating minimal human toxicity in either short term or long term studies.  Currently, there is no vaccine strategy against CMV applicable to HCT recipients that uses a recombinant MVA incorporating multiple cellular response antigens.  Three CMV gene products, UL83 (pp65), UL122 (IE2), and UL123 (IE1) have been selected as targets for cell mediated immune response.  We have termed this vaccine as CMV-MVA Triplex, which was manufactured and is currently being tested at the City of Hope.  This study will compare the immune response of CMV-MVA Triplex vaccine used in persons with no prior CMV immunity and in those with prior CMV immunity.  The primary goal of this first in humans clinical trial is to establish the safety of the CMV-MVA Triplex vaccine given to healthy volunteers ( Project 3 ).  A future study is being finalized to investigate the safety and protective function of the vaccine in our HCT population.  Additional studies are envisioned in the solid organ transplant setting.
 
Fetal infection by HCMV during and after pregnancy poses a serious health risk to the developing child. Thus, a vaccine that confers protective immunity against congenital CMV infection is another significant focus of the TVR. In collaboration with the University of California at Davis and the California National Primate Research Center (CNPRC), the TVR is utilizing rhesus macaques (RM) as a primate model for HCMV infection and testing congenital vaccine concepts.  The close phylogenetic relation of humans and RM makes them a pivotal animal model for this study. In addition, the rhesus (Rh)CMV genome is largely co-linear to that of HCMV and encodes orthologs for all 5 subunits of the gH/gL-pentameric complex, termed gH/gL-PC (UL128, UL130, UL131A, gH and gL).  Previous studies have shown that neutralizing antibodies (NAb) are crucial in the host immune response to control or prevent the infection with HCMV.  Promising progress in the development of an HCMV vaccine has been made by a strategy based on a recombinant form of the envelope glycoprotein B (gB), a dominant NAb target in HCMV-positive individuals.  Based on these findings, scientists in the Division have developed a bacterial artificial chromosome (BAC)-derived Modified Vaccinia Ankara (MVA) vaccine vector co-expressing all 5 subunits of the gH/gL-PC (MVA-gH/gL-PC), which is considered as the major target of NAb that block the infection of epithelial and endothelial cells (EC). Focus of current work involves the characterization and isolation of the gH/gL-PC, and identification of gH/gL-PC-specific NAb responses and their epitope targets.  Generation of a multi-antigenic BAC-derived MVA vaccine vector that incorporates the gH/gL-PC in combination with other dominant NAb targets (gB, gH/gL, gH/gL/gO, gM, gN) and major targets of the cell-mediated arm of immunity such as pp65 and IE1 are also major efforts ( Project 5 and  Project 6 ).
 

Oncotherapeutics

Advanced pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and can be attributed to deficiencies in early detection methods and effective therapies. Overexpression of indoleamine 2,3-dioxygenase (IDO) in PDAC plays a major role in accelerating disease progression by suppressing antitumor immunity. shIDO-ST is a novel Salmonella typhimirium (ST)-based therapy that expresses a small hairpin (sh) RNA to specifically silence tumor-derived IDO with decreased toxicity. ST as an shRNA delivery vehicle offers superior penetration against desmoplastic PDAC tissue and anti-metastatic function due to its motility and affinity for poorly vascularized, hypoxic tissue.  Using bioluminescent forms of cell lines derived from pancreatic tumors, the TVR is able to employ advanced imaging techniques to follow therapeutic strategies in which Salmonella therapy is combined with proprietary adjuvant causing remarkable complete rejection of transplantable tumors ( Project 7 ).  To further understand the molecular mechanisms leading to PDAC tumor cell death, Project 9 focuses on inhibitory immune-checkpoints receptors such as programmed death 1 (PD1) and its ligand (PD-L1) whose expression have been significantly associated with various types of cancer, including PDAC.  Studies are being conducted to best assess anti-PD1 mAb using  genetically engineered orthotopic Kras and p53 mutant (KPC) PDAC mouse models that recapitulates desmoplasia and metastasis characteristic of human PDAC.  The long-term objective of this study is to better understand the molecular mechanism of PD-1 action that causes clinical remission of many solid tumors. 
 
The p53 protein is a well-characterized suppressor of uncontrolled cell division.  Mutations in the gene occur > 50% of all patients with solid tumors, whereby it acquires oncogenic properties, and leads to high levels of dysfunctional p53 protein with malignant cells.  The concentration of normal, non-mutant p53 in healthy cells is low, making p53 an attractive target for selective killing of tumor cells.  To generate robust anti-p53 immune responses, a vaccine delivery platform was developed based on a highly attenuated virus referred to as Modified Vaccinia Ankara (MVA). Preclinical studies developed in our Division have shown that immunization of mice with p53-MVA vaccine causes rejection of established tumors and generation of systemic tumor immunity.  In addition, when p53-MVA was used to generate cytotoxic T cells from the blood of cancer patients, these were capable of killing tumor cells in vitro.   Recombinant MVA vaccinies have an impressive safety record, being administered in numerous clinical trials with only mild-side effects.  Earlier this year, a first in human, Phase I clinical trial evaluating the safety and immunogenicity of clinical grade p53MVA vaccine in patients with colon and pancreatic cancers was completed.  A planned phase II clinical trial will involve p53-MVA vaccination early after diagnosis to test efficacy of the  vaccine as a multimodal therapy in combination with standard chemotherapy or with immunologic check point inhibitors such as CTLA-4 or PD-1 ( Project 4 ).
 
The role of suppressive hematopoietic cells in tumor immune evasion and cancer progression is well known. One method of depleting these suppressive cell types is with standard chemotherapy agents such as gemcitabine, which is reported to induce positive immunomodulatory effects in pancreatic cancer patients. Gemcitabine is often used to treat platinum resistant ovarian cancer, which has a very poor outcome. Our forthcoming clinical study will evaluate the p53MVA vaccine in combination with gemcitabine in chemotherapy-refractory ovarian cancer patients with the aim of enhancing the stimulatory action of p53MVA and delivering clinical benefit ( Project 4 ).
 
Relapse is a major obstacle to maximizing curative potential of allogeneic HCT (aHCT) therapy for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). WT1 has been investigated as a tumor marker in a variety of studies which have shown its association with disease progression and relapse. TVR personnel are applying this important biomarker as part of standard diagnostic procedures for detection of relapse in the highest-risk individuals – acute leukemia and MDS patients undergoing aHCT ( Project 9 ). Furthermore, we are using WT1 as a potential therapeutic vaccine antigen in combination with adjuvants and checkpoint inhibitors, such as PD1, for patients with hematologic malignancies. The hope is that an effective adaptive immune response is generated that can recognize and ablate tumors and metastases over-expressing the WT1 oncogene.
 

Current Experimental Therapeutics Projects

Evaluation of safety and correlative immunogenicity studies of CMVPepVax co-injected with PF03512676 adjuvant in recipients of allogeneic stem cell transplant
 
CMVPepVax to protect stem cell transplant recipients from Cytomegalovirus infection-University of Minnesota collaborative study
 
Control of CMV infection in allogeneic stem cell transplant recipients using attenuated MVA-based CMV subunit vaccine
 
A Phase I study of a p53-MVA vaccine for advanced colon, gastric and pancreatic cancer
 
HCMV vaccine Produced from BAC-MVA that blocks epithelial and fibroblast entry
 
Evaluation of protective CMV vaccines in rhesus macaques
 
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
 
WT1 as a biomarker topredict relapse in patients with acute leukemia and MDS
 
Pilot Project: Blockade of immune checkpoint receptors for the treatment of pancreatic cancer
 

Experimental Therapeutics Lab Members

Current Grant Support for Don J. Diamond, PhD

02/10 - 01/16
5R01 AI063356-09 (Barry & Diamond)
NIAID Evaluation of Protective CMV Vaccines in Rhesus Macaques The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator
 
06/15 - 05/19
Fortress (Coronado) Biosciences SRA 
Accelerating clinical development of CMVPepVax, CMV-MVA Triplex and CMVConVAX
Role: Principal Investigator
 
 
10/14 – 08/19
1R01HL122216 (Miller)
NIH
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection. Pending Review.
Role: Co-Investigator
 
10/14 – 07/19
1R01CA181045-01
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
CMVPepVax will be comprehensively evaluated in HLA-A2 hematopoietic cell transplant (HCT) recipients to discover the optimal formula for immunizing both donors and recipients to prevent CMV viremia
Role: Principal Investigator
 
05/12 - 12/17
5R01 CA077544-13
NCI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator
 
05/13 – 04/17
R01 AI103960-02 (Diamond & Barry)
NIH
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)
 
04/12 – 08/15
Nesvig Foundation Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator
 
07/13 – 06/16
R21 CA0174306-02
NIH
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Role: Principal Investigator
 
01/14–09/16
p53MVA Pipeline Project Award
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
The p53-MVA vaccine will be given concurrently with other immunomodulatory agents, such as checkpoint inhibitor monoclonal antibodies (e.g. Ipilimumab and/or Nivolumab or Pembrolizumab), with the aim of extending disease progression-free survival.
Role: Principal Investigator

About Don J. Diamond, Ph.D.

Don J. Diamond, Ph.D., chairs the  Department of Experimental Therapeutics, which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) HIV.

The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients.  A therapeutic CMV peptide vaccine developed in the department is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, is currently undergoing phase I human safety testing.

A vaccine developed in the department also based on the MVA platform expressing unmutated p53 has completed phase I human testing in City of Hope gastrointestinal cancer patients.  In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers.  In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

Professional Experience
 
  • 2014 - Present, Chair and Professor, Department of Experimental Therapeutics
  • 2013 - 2014,  Associate Chair, Department of Virology
  • 2008 - 2014, Director, Division of Translational Vaccine Research, Beckman Research Institute of City of Hope, Duarte, CA
  • 1999 - 2014, Professor, Department of Virology, Beckman Research Institute
  • 1999 - 2008, Head, Laboratory of Vaccine Research, Department of Virology, Beckman Research Institute
  • 1994 - 1999, Associate Research Scientist, Hematology Research, City of Hope, Duarte, CA
  • 1989 - 1994, Assistant Research Scientist and Section Head, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 1986 - 1989, Research Fellow and Instructor in Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
  • 1985 - 1987, Leukemia Society of America Fellow with E. Reinherz, M.D., DFCI, Harvard Medical School, Boston, MA
  • 1984 - 1986, Postdoctoral Fellow with S. Tonegawa, Ph.D., Center for Cancer Research, MA, MIT, Cambridge, MA
     
 
 
 
 

Experimental Therapeutics

Department of Experimental Therapeutics

The Laboratory of Vaccine Research (LVR) was originally formed by  Don J. Diamond, Ph.D. in 2000 to address priorities in vaccine research that would potentially impact patient outcomes at the City of Hope (COH) and other cancer centers worldwide.  The LVR later evolved into the Division of Translational Vaccine Research (TVR) in 2008, which has, since then, focused on the clinical translation of vaccine and therapeutic strategies to combat herpes viral infections, hematologic malignancies, and solid tumors. Our comprehensive program has now developed molecular vaccines and therapies that incorporate various technologies such as peptides and viral or bacterial vectors to directly elicit, or encode antigens that elicit, viral- or cancer-specific immune responses. Currently, the TVR has produced several agents that have advanced beyond pre-clinical testing into Phase I and II trials. The mission of the TVR is to continue progress in the development and testing of treatments with clinical benefit for cancer patients.  In 2014, the TVR was transformed into the Department of Experimental Therapeutics (ET).  The mission of the ET department will encompass the work of the TVR and broaden its scope to include more basic studies in basic and tumor immunology.

Human Cytomegalovirus
 
Allogeneic hematopoietic cell transplantation (HCT) is a therapy for which COH is a world leader and is effective for a range of life-threatening hematologic malignancies. However, one of the most difficult-to-treat complications can occur during the first 100 days post-HCT, which is infection with the highly prevalent beta-herpes virus known as human cytomegalovirus (HCMV).  HCMV rarely causes disease in healthy individuals, but can be life-threatening in HCT patients as a result of immunosuppression associated with treatment strategies aimed at preventing rejection or graft-versus-host disease (GVHD).  To improve outcomes for HCT recipients, the ET aims to substitute toxic antivirals with a vaccine that induces long-lasting, memory immune responses to HCMV, since antivirals are unable to generate adaptive immunity capable of preventing HCMV infection and disease.  Learn more.
 

Oncotherapeutics
 
Advanced pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and can be attributed to deficiencies in early detection methods and effective therapies. Overexpression of indoleamine 2,3-dioxygenase (IDO) in PDAC plays a major role in accelerating disease progression by suppressing antitumor immunity. shIDO-ST is a novel Salmonella typhimirium (ST)-based therapy that expresses a small hairpin (sh) RNA to specifically silence tumor-derived IDO with decreased toxicity. ST as an shRNA delivery vehicle offers superior penetration against desmoplastic PDAC tissue and anti-metastatic function due to its motility and affinity for poorly vascularized, hypoxic tissue.  Using bioluminescent forms of cell lines derived from pancreatic tumors, the TVR is able to employ advanced imaging techniques to follow therapeutic strategies in which Salmonella therapy is combined with proprietary adjuvant causing remarkable complete rejection of transplantable tumors.  Learn more.
 

Human Cytomegalovirus

Human Cytomegalovirus

Allogeneic hematopoietic cell transplantation (HCT) is a therapy for which City of Hope is a world leader and is effective for a range of life-threatening hematologic malignancies. However, one of the most difficult-to-treat complications can occur during the first 100 days post-HCT, which is infection with the highly prevalent beta-herpes virus known as human cytomegalovirus (HCMV).  HCMV rarely causes disease in healthy individuals, but can be life-threatening in HCT patients as a result of immunosuppression associated with treatment strategies aimed at preventing rejection or graft-versus-host disease (GVHD).  To improve outcomes for HCT recipients, the TVR aims to substitute toxic antivirals with a vaccine that induces long-lasting, memory immune responses to HCMV, since antivirals are unable to generate adaptive immunity capable of preventing HCMV infection and disease.
 
In allogeneic HCT, hematopoietic cells are obtained from suitable HLA matched related or unrelated volunteer donors (URD).  Pretransplant patients are treated with chemotherapy, with or without radiation therapy, to eradicate cancerous cells, and for suppressing the patient’s immune system to prevent it from attacking donor hematopoietic cells.  As a result, patients are vulnerable to pathogens and herpes virus infections, including CMV, as a result of immunosuppression associated with treatment strategies aimed at preventing rejection or graft-versus-host disease (GVHD).  Despite advances in development of antiviral therapy, the use of antivirals does not address the major risks of late-onset CMV disease, including reactivation and failure to reconstitute CMV-specific immunity.  Substituting toxic antivirals with a vaccine that harnesses the abundant native immune response to CMV may improve outcomes for HCT recipients.
 
Our first generation vaccine approach relied on a non-living synthetic portion of the virus called a peptide that has cleared its safety hurdle after a successful clinical trial in healthy volunteers. The vaccine peptides were named PADRE-CMV and Tet-CMV, respectively, and were developed with support of the National Cancer Institute sponsored Rapid Access to Interventional Development (NCI-RAID, currently called NCI-NExT) program.  After obtaining approval from the FDA, PADRE-CMV and Tet-CMV, with or without PF-03512676 adjuvant (a synthetic single stranded DNA containing bacterial CpG DNA motifs with immunostimulatory activity, produced by Pfizer, Inc.), were clinically evaluated for safety and immunogenicity in a Phase Ib dose-escalation clinical trial.  The achievement of the central goal of our phase Ib study in healthy adults supports further evaluation of Tet-CMV combined with PF-03512676 (renamed CMVPepVax)  in the HCT setting. A summary of the results of the trial was published in 2012. These promising results are the basis for CMVPepVax as a therapeutic vaccine, to improve outcomes of HCT recipients with uncontrolled CMV viremia. The phase Ib pilot trial was powered to evaluate safety of administering CMVPepVax to HLA matched allogeneic (MRD or URD) patients at risk for CMV complications ( Project 1 ).  To capitalize on the success of the pilot Phase Ib trial, NCI approved a fresh lot of vaccine to support a large multi-center Phase II study jointly with the University of Minnesota Comprehensive Cancer Center.  The goal of this Phase II clinical trial is to assess efficacy of CMVPepVax, in protecting against CMV reactivation and disease ( Project 2 ).
 
As a viral vector that can incorporate foreign antigens and protect against a challenge pathogen, modified vaccinia Ankara (MVA) virus is hypothesized to act as a powerful immunotherapeutic tool against multiple strains of CMV regardless of an individual’s HLA type (Projects 3-6). The potential value of MVA for the clinic stems from its ability to elicit strong humoral and T cell responses against diverse antigens. Studies in rodents and macaques affirm the safety of MVA, including protection against more virulent forms of poxviruses.  There are over 150 active clinical studies using MVA that are documented on the USPHS website.  Recent trials have shown MVA is well tolerated and immunogenic when administered to HCT recipients, indicating minimal human toxicity in either short term or long term studies.  Currently, there is no vaccine strategy against CMV applicable to HCT recipients that uses a recombinant MVA incorporating multiple cellular response antigens.  Three CMV gene products, UL83 (pp65), UL122 (IE2), and UL123 (IE1) have been selected as targets for cell mediated immune response.  We have termed this vaccine as CMV-MVA Triplex, which was manufactured and is currently being tested at the City of Hope.  This study will compare the immune response of CMV-MVA Triplex vaccine used in persons with no prior CMV immunity and in those with prior CMV immunity.  The primary goal of this first in humans clinical trial is to establish the safety of the CMV-MVA Triplex vaccine given to healthy volunteers ( Project 3 ).  A future study is being finalized to investigate the safety and protective function of the vaccine in our HCT population.  Additional studies are envisioned in the solid organ transplant setting.
 
Fetal infection by HCMV during and after pregnancy poses a serious health risk to the developing child. Thus, a vaccine that confers protective immunity against congenital CMV infection is another significant focus of the TVR. In collaboration with the University of California at Davis and the California National Primate Research Center (CNPRC), the TVR is utilizing rhesus macaques (RM) as a primate model for HCMV infection and testing congenital vaccine concepts.  The close phylogenetic relation of humans and RM makes them a pivotal animal model for this study. In addition, the rhesus (Rh)CMV genome is largely co-linear to that of HCMV and encodes orthologs for all 5 subunits of the gH/gL-pentameric complex, termed gH/gL-PC (UL128, UL130, UL131A, gH and gL).  Previous studies have shown that neutralizing antibodies (NAb) are crucial in the host immune response to control or prevent the infection with HCMV.  Promising progress in the development of an HCMV vaccine has been made by a strategy based on a recombinant form of the envelope glycoprotein B (gB), a dominant NAb target in HCMV-positive individuals.  Based on these findings, scientists in the Division have developed a bacterial artificial chromosome (BAC)-derived Modified Vaccinia Ankara (MVA) vaccine vector co-expressing all 5 subunits of the gH/gL-PC (MVA-gH/gL-PC), which is considered as the major target of NAb that block the infection of epithelial and endothelial cells (EC). Focus of current work involves the characterization and isolation of the gH/gL-PC, and identification of gH/gL-PC-specific NAb responses and their epitope targets.  Generation of a multi-antigenic BAC-derived MVA vaccine vector that incorporates the gH/gL-PC in combination with other dominant NAb targets (gB, gH/gL, gH/gL/gO, gM, gN) and major targets of the cell-mediated arm of immunity such as pp65 and IE1 are also major efforts ( Project 5 and  Project 6 ).
 

Oncotherapeutics

Oncotherapeutics

Advanced pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and can be attributed to deficiencies in early detection methods and effective therapies. Overexpression of indoleamine 2,3-dioxygenase (IDO) in PDAC plays a major role in accelerating disease progression by suppressing antitumor immunity. shIDO-ST is a novel Salmonella typhimirium (ST)-based therapy that expresses a small hairpin (sh) RNA to specifically silence tumor-derived IDO with decreased toxicity. ST as an shRNA delivery vehicle offers superior penetration against desmoplastic PDAC tissue and anti-metastatic function due to its motility and affinity for poorly vascularized, hypoxic tissue.  Using bioluminescent forms of cell lines derived from pancreatic tumors, the TVR is able to employ advanced imaging techniques to follow therapeutic strategies in which Salmonella therapy is combined with proprietary adjuvant causing remarkable complete rejection of transplantable tumors ( Project 7 ).  To further understand the molecular mechanisms leading to PDAC tumor cell death, Project 9 focuses on inhibitory immune-checkpoints receptors such as programmed death 1 (PD1) and its ligand (PD-L1) whose expression have been significantly associated with various types of cancer, including PDAC.  Studies are being conducted to best assess anti-PD1 mAb using  genetically engineered orthotopic Kras and p53 mutant (KPC) PDAC mouse models that recapitulates desmoplasia and metastasis characteristic of human PDAC.  The long-term objective of this study is to better understand the molecular mechanism of PD-1 action that causes clinical remission of many solid tumors. 
 
The p53 protein is a well-characterized suppressor of uncontrolled cell division.  Mutations in the gene occur > 50% of all patients with solid tumors, whereby it acquires oncogenic properties, and leads to high levels of dysfunctional p53 protein with malignant cells.  The concentration of normal, non-mutant p53 in healthy cells is low, making p53 an attractive target for selective killing of tumor cells.  To generate robust anti-p53 immune responses, a vaccine delivery platform was developed based on a highly attenuated virus referred to as Modified Vaccinia Ankara (MVA). Preclinical studies developed in our Division have shown that immunization of mice with p53-MVA vaccine causes rejection of established tumors and generation of systemic tumor immunity.  In addition, when p53-MVA was used to generate cytotoxic T cells from the blood of cancer patients, these were capable of killing tumor cells in vitro.   Recombinant MVA vaccinies have an impressive safety record, being administered in numerous clinical trials with only mild-side effects.  Earlier this year, a first in human, Phase I clinical trial evaluating the safety and immunogenicity of clinical grade p53MVA vaccine in patients with colon and pancreatic cancers was completed.  A planned phase II clinical trial will involve p53-MVA vaccination early after diagnosis to test efficacy of the  vaccine as a multimodal therapy in combination with standard chemotherapy or with immunologic check point inhibitors such as CTLA-4 or PD-1 ( Project 4 ).
 
The role of suppressive hematopoietic cells in tumor immune evasion and cancer progression is well known. One method of depleting these suppressive cell types is with standard chemotherapy agents such as gemcitabine, which is reported to induce positive immunomodulatory effects in pancreatic cancer patients. Gemcitabine is often used to treat platinum resistant ovarian cancer, which has a very poor outcome. Our forthcoming clinical study will evaluate the p53MVA vaccine in combination with gemcitabine in chemotherapy-refractory ovarian cancer patients with the aim of enhancing the stimulatory action of p53MVA and delivering clinical benefit ( Project 4 ).
 
Relapse is a major obstacle to maximizing curative potential of allogeneic HCT (aHCT) therapy for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). WT1 has been investigated as a tumor marker in a variety of studies which have shown its association with disease progression and relapse. TVR personnel are applying this important biomarker as part of standard diagnostic procedures for detection of relapse in the highest-risk individuals – acute leukemia and MDS patients undergoing aHCT ( Project 9 ). Furthermore, we are using WT1 as a potential therapeutic vaccine antigen in combination with adjuvants and checkpoint inhibitors, such as PD1, for patients with hematologic malignancies. The hope is that an effective adaptive immune response is generated that can recognize and ablate tumors and metastases over-expressing the WT1 oncogene.
 

Research Projects

Current Experimental Therapeutics Projects

Evaluation of safety and correlative immunogenicity studies of CMVPepVax co-injected with PF03512676 adjuvant in recipients of allogeneic stem cell transplant
 
CMVPepVax to protect stem cell transplant recipients from Cytomegalovirus infection-University of Minnesota collaborative study
 
Control of CMV infection in allogeneic stem cell transplant recipients using attenuated MVA-based CMV subunit vaccine
 
A Phase I study of a p53-MVA vaccine for advanced colon, gastric and pancreatic cancer
 
HCMV vaccine Produced from BAC-MVA that blocks epithelial and fibroblast entry
 
Evaluation of protective CMV vaccines in rhesus macaques
 
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
 
WT1 as a biomarker topredict relapse in patients with acute leukemia and MDS
 
Pilot Project: Blockade of immune checkpoint receptors for the treatment of pancreatic cancer
 

Experimental Therapeutics Lab Members

Experimental Therapeutics Lab Members

Grant Support

Current Grant Support for Don J. Diamond, PhD

02/10 - 01/16
5R01 AI063356-09 (Barry & Diamond)
NIAID Evaluation of Protective CMV Vaccines in Rhesus Macaques The major goal of this project is to construct and evaluate MVA-based vaccines that target the endocytic pathway of infection using a validated RhCMV challenge model that exhibits shedding and systemic infection.
Role: PD/Principal Investigator
 
06/15 - 05/19
Fortress (Coronado) Biosciences SRA 
Accelerating clinical development of CMVPepVax, CMV-MVA Triplex and CMVConVAX
Role: Principal Investigator
 
 
10/14 – 08/19
1R01HL122216 (Miller)
NIH
Inducing NK cells to remember and fight cancer
Provide regular consults and provide insight into the natural history of CMV infection in transplant recipients and the role of adaptive and innate immunity to control the infection. Pending Review.
Role: Co-Investigator
 
10/14 – 07/19
1R01CA181045-01
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
CMVPepVax will be comprehensively evaluated in HLA-A2 hematopoietic cell transplant (HCT) recipients to discover the optimal formula for immunizing both donors and recipients to prevent CMV viremia
Role: Principal Investigator
 
05/12 - 12/17
5R01 CA077544-13
NCI
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine The major goal of this continuation project is to evaluate a multi-subunit CMV vaccine in human subjects including a safety study in healthy adults and a therapeutic trial in HCT recipients.
Role: Principal Investigator
 
05/13 – 04/17
R01 AI103960-02 (Diamond & Barry)
NIH
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry The major goals are to construct an MVA expressing Human-UL128 pentamer using BAC-MVA technology, immunization of RhCMV-negative monkeys, and characterize humoral responses that inhibit CMV infection of fibroblasts and epithelial cells, with and without pp65-gB-MVA.
Role: PD/Principal Investigator (Contact)
 
04/12 – 08/15
Nesvig Foundation Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems The major goal of this project is to develop a gene-targeting silencing approach to attenuate B-cell lymphoma applicable to future clinical adaptation.
Role: Principal Investigator
 
07/13 – 06/16
R21 CA0174306-02
NIH
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC The major goal of the R21 is to evaluate and optimize an IDO-silencing Salmonella-based therapy (shIDO-ST) for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Role: Principal Investigator
 
01/14–09/16
p53MVA Pipeline Project Award
Phase 1 study combining a p53MVA vaccine with ipilimumab and nivolumab
The p53-MVA vaccine will be given concurrently with other immunomodulatory agents, such as checkpoint inhibitor monoclonal antibodies (e.g. Ipilimumab and/or Nivolumab or Pembrolizumab), with the aim of extending disease progression-free survival.
Role: Principal Investigator

Current Job Openings

About Don J. Diamond, Ph.D.

About Don J. Diamond, Ph.D.

Don J. Diamond, Ph.D., chairs the  Department of Experimental Therapeutics, which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) HIV.

The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients.  A therapeutic CMV peptide vaccine developed in the department is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, is currently undergoing phase I human safety testing.

A vaccine developed in the department also based on the MVA platform expressing unmutated p53 has completed phase I human testing in City of Hope gastrointestinal cancer patients.  In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers.  In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

Professional Experience
 
  • 2014 - Present, Chair and Professor, Department of Experimental Therapeutics
  • 2013 - 2014,  Associate Chair, Department of Virology
  • 2008 - 2014, Director, Division of Translational Vaccine Research, Beckman Research Institute of City of Hope, Duarte, CA
  • 1999 - 2014, Professor, Department of Virology, Beckman Research Institute
  • 1999 - 2008, Head, Laboratory of Vaccine Research, Department of Virology, Beckman Research Institute
  • 1994 - 1999, Associate Research Scientist, Hematology Research, City of Hope, Duarte, CA
  • 1989 - 1994, Assistant Research Scientist and Section Head, Department of Immunology, Beckman Research Institute of City of Hope, Duarte, CA
  • 1986 - 1989, Research Fellow and Instructor in Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
  • 1985 - 1987, Leukemia Society of America Fellow with E. Reinherz, M.D., DFCI, Harvard Medical School, Boston, MA
  • 1984 - 1986, Postdoctoral Fellow with S. Tonegawa, Ph.D., Center for Cancer Research, MA, MIT, Cambridge, MA
     
 
 
 
 
Media
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Welcome to City of Hope
City of Hope is a new model of cancer center, focused on rapidly transforming scientific discoveries into better treatments and better prevention strategies for cancer, diabetes, HIV/AIDS and other life-threatening diseases.

Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • Approximately one in eight women will be diagnosed with breast cancer during her lifetime. Although the disease can have a profound impact on the patient and her loved ones, it can often be effectively treated with surgery, radiation therapy, hormone therapy and chemotherapy. Skin- and nipple-sparing surgeries,...
  • City of Hope is a leader in the diagnosis and treatment of skin cancer and precancerous conditions. Our multidisciplinary team of health care professionals takes an integrated approach to treating this disease by combining the latest research findings with outstanding patient care. In this podcast, Hans Schoell...
  • Patients with chronic lymphocytic leukemia may soon find themselves with improved treatment options. Interim results from a study not conducted at City of Hope suggest that, for patients with chronic lymphocytic leukemia, or CLL, a new oral drug given in combination with standard treatment significantly reduced...
  • The childhood journal of Kevin Chan, M.D., foreshadowed his future: At the tender age of 6, he wrote that he wanted to be a surgeon when he grew up. “I liked the idea of fixing broken arms and legs,” Chan said. “Back then, those were the procedures I could relate to.” Although his passion for […]
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...
  • If there is one truism about hospital stays it is that patients want to get out. For many, however, the joy of being discharged is tempered by the unexpected challenges that recovery in a new setting may pose. Even with professional help, the quality of care and treatment that patients receive at City of Hope [...